Free Newsletter
Scientists offer new research path for eradicating HIV
Drugs can stop HIV from progressing, but until now researchers have been stumped in their efforts to eradicate the deadly virus.
Now a team of researchers from VGTI Florida and the University of Montreal say that they have identified subsets of memory T-cells where the virus can linger, hidden within the body's immune system. And HIV replicates itself in the T-cells through cell division, a completely different replication process that takes place in other cells. New drugs can be developed to stop both mechanisms, they say, offering a new research avenue that can ultimately defeat HIV.
"Based on this research, we believe one possible method for eliminating HIV in the body is to use a combined approach," Rafick-Pierre Sékaly, Ph.D., current scientific director for VGTI Florida. "We propose the use of medications that target viral replication of HIV throughout the body, in combination with drugs that prevent infected memory T-cells from dividing. We believe that by attacking the disease in these distinct two ways at once for an extended period of time, we can eliminate the reservoirs of HIV that currently persist within the human body, leaving an individual disease-free."
- read the press release
Related Articles:
Woman's immune system may be key to HIV vax
HIV vax debacle linked to T-cell activation
HIV research summit seeks new discovery path
Fauci says HIV vaccine requires a new approach
Comments
"New Paradigm in HIV-related Research"
Until now, patients rely heavily if not solely on the cocktail-method in the treatment of HIV/AIDs-related symptoms/disease. This is sofar the most effective treatment in almost all countries. However, this near-consensus method of treatment is not only contentious but also unreliable.
With advance breakthrough in genetic R&D, scientists may be able to unravel and discover the path/door/enabler/driver towards a clearer identification of a better methodology in the treatment process-one that is cost effective and certainly less painful.
Jeong Chun phuoc
lecturer-in-Law
Jeongphu@yahoo.com
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: